# Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

> **NCT05454410** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Treatment-Resistant Depression

## Interventions

- **DRUG:** MIJ821 Subcutaneous Injection 1 mg
- **DRUG:** MIJ821 Subcutaneous Injection 4 mg
- **DRUG:** MIJ821 Subcutaneous Injection 10 mg
- **DRUG:** Placebo Subcutaneous Injection

## Key facts

- **NCT ID:** NCT05454410
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-13
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05454410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05454410, "Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05454410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*